| Family: | ProShares |
| Name: | ProShares Ultra Nasdaq Biotechnology |
| Inception Date: | 7-Apr-2010 |
| Termination Date: | |
| Investment Objective: | ProShares Ultra Nasdaq Biotechnology seeks daily investment results before fees and expenses that correspond to twice (200%) the daily performance of the NASDAQ Biotechnology Index. |
| Prospectus | |
| Top 10 Holdings | ||
| Derivatives offset | -138.1668% | |
| NASDAQ Bio Index SWAP BNP Paribas | 39.2032% | |
| Net Other Assets (Liabilities) | 31.7998% | |
| NASDAQ Biotechnology Index SWAP Citibank NA | 28.1771% | |
| NASDAQ Biotechnology Index SWAP Bank of America NA | 24.5310% | |
| NASDAQ Biotechnology Index SWAP Goldman Sachs International | 21.1008% | |
| NASDAQ Biotechnology Index SWAP Societe Generale | 20.0934% | |
| PROSHARES GENIUS MNY MKT ETF | IQMM | 6.5268% |
| NASDAQ Biotechnology Index SWAP UBS AG | 5.0613% | |
| VERTEX PHARMACEUTICALS INC | VRTX | 5.0478% |
| Top 10 Holdings Weight: | 43.4% |
| Number of Holdings: | 262 |
| Shares Outstanding: | 870,000 |
| Total Net Assets: | 76,568,700 |
| NAV: | 88.17 |
| Net Expense Ratio: | 0.95% |
| Asset Class: | Equities (Stocks) |
| Developed or Emerging: | Developed Market Funds |
| Country: | US |
| Region: | |
| Strategy: | |
| Currency: | |
| Commodity: | |
| Sector: | Healthcare |
| Industry: | Biotech |
| Dividend Type: | |
| Tax Exempt State: | |
| Maturity Duration: | |
| Market Cap: | Broad Market / Multi-Cap |
| Credit Quality: | |
| Mortgage Bond Types: | |
| Bond Type: | |
| Gov't Bond Types: | |
| Reit Type: | |
| Leverage Direction/Factor: | Leveraged (2x) |
| Is Currency Hedged: | No |
| US or Ex-US: | Domestic |
